Update tsv, md and png files

Author: actions-user

_data/WP4969-bibliography.tsv

@@ -4,7 +4,7 @@ ID	Database	Citation
 10320667	Pubmed	"Guanylate cyclase and the .NO/cGMP signaling pathway. Denninger JW, Marletta MA. Biochim Biophys Acta. 1999 May 5;1411(2–3):334–50.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/10320667"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/10320667"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/10320667"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
 15174896	Pubmed	"Pharmacogenetics of antihypertensive drug responses. Schwartz GL, Turner ST. Am J Pharmacogenomics. 2004;4(3):151–60.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/15174896"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/15174896"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/15174896"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
 18035185	Pubmed	"Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR. Clin Ther. 2007 Sep;29(9):1803–24.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/18035185"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/18035185"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/18035185"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
-18040024	Pubmed	"cGMP-dependent protein kinase I and smooth muscle relaxation: a tale of two isoforms. Surks HK. Circ Res. 2007 Nov 26;101(11):1078–80.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/18040024"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/18040024"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/18040024"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
+18086946	Pubmed	"Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis. Li P, Kondo T, Numaguchi Y, Kobayashi K, Aoki M, Inoue N, et al. Hypertension. 2008 Feb;51(2):252–8.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/18086946"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/18086946"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/18086946"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
 18449520	Pubmed	"Are we poised to target ACE2 for the next generation of antihypertensives? Ferreira AJ, Raizada MK. J Mol Med (Berl). 2008 Jun;86(6):685–90.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/18449520"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/18449520"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/18449520"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
 32526773	Pubmed	"Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection. de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C. Semin Thromb Hemost. 2020 Oct;46(7):835–7.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/32526773"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/32526773"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/32526773"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
 32562843	Pubmed	"COVID-19 and pneumonia: a role for the uPA/uPAR system. D’Alonzo D, De Fenza M, Pavone V. Drug Discov Today. 2020 Aug;25(8):1528–34.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/32562843"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/32562843"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/32562843"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"

_pathways/WP4969.md

@@ -1,17 +1,17 @@
 ---
 annotations:
-- id: PW:0000013
-  parent: disease pathway
-  type: Pathway Ontology
-  value: disease pathway
-- id: DOID:0080600
-  parent: disease by infectious agent
-  type: Disease Ontology
-  value: COVID-19
 - id: CL:0000359
   parent: native cell
   type: Cell Type Ontology
   value: vascular associated smooth muscle cell
+- id: DOID:0080600
+  parent: disease by infectious agent
+  type: Disease Ontology
+  value: COVID-19
+- id: PW:0000013
+  parent: disease pathway
+  type: Pathway Ontology
+  value: disease pathway
 authors:
 - Khanspers
 - Egonw
@@ -23,43 +23,44 @@ authors:
 citedin: ''
 communities:
 - COVID19
-description: 'This pathway describes imbalances in RAS and Bradykinin pathways in
-  COVID-19.  The expression of several genes in these pathways is affected in by SARS-CoV-2:   *
-  SERPING1 is downregulated, which cancels the suppression of F12 of the intrinsic
-  coagulation cascade, resulting in the production of bradykinin from kallikrein and
-  KNG. * ACE is downregulated, which increases bradykinin levels. * ACE2 is upregulated,
-  ACE is downregulated, which causes an increase in Angiotensin 1-9 and sensitization
-  of bradykinin receptors. * NFkappaB is suppressed by SARS-Cov-2, decreasing its
-  binding to the ACE promoter and subsequent transcription.  The result of a hyperactive
-  bradykinin system is vasodilation to the point of vascular leakage and infiltration
-  of inflammatory cells.  The pathway is based on Figure 2A from [Garvin et al.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410499/).'
-last-edited: 2025-08-01
+description: This pathway describes imbalances in the Renin Angiotensin System and
+  Bradykinin pathways in COVID-19.  The expression of several genes in these pathways
+  is affected in by SARS-CoV-2. SERPING1 is downregulated, which cancels the suppression
+  of F12 of the intrinsic coagulation cascade, resulting in the production of bradykinin
+  from kallikrein and KNG. ACE is downregulated, which increases bradykinin levels.
+  ACE2 is upregulated, ACE is downregulated, which causes an increase in Angiotensin
+  1-9 and sensitization of bradykinin receptors. NFkappaB is suppressed by SARS-Cov-2,
+  decreasing its binding to the ACE promoter and subsequent transcription.  The result
+  of a hyperactive bradykinin system is vasodilation to the point of vascular leakage
+  and infiltration of inflammatory cells.  The pathway is based on Figure 2A from
+  [Garvin et al.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410499/).
+last-edited: 2025-12-16
 ndex: 1a2a785b-8b74-11eb-9e72-0ac135e8bacf
 organisms:
 - Homo sapiens
 redirect_from:
 - /index.php/Pathway:WP4969
 - /instance/WP4969
-- /instance/WP4969_r140128
-revision: r140128
+- /instance/WP4969_r142202
+revision: r142202
 schema-jsonld:
 - '@context': https://schema.org/
   '@id': https://wikipathways.github.io/pathways/WP4969.html
   '@type': Dataset
   creator:
     '@type': Organization
     name: WikiPathways
-  description: 'This pathway describes imbalances in RAS and Bradykinin pathways in
-    COVID-19.  The expression of several genes in these pathways is affected in by
-    SARS-CoV-2:   * SERPING1 is downregulated, which cancels the suppression of F12
-    of the intrinsic coagulation cascade, resulting in the production of bradykinin
-    from kallikrein and KNG. * ACE is downregulated, which increases bradykinin levels.
-    * ACE2 is upregulated, ACE is downregulated, which causes an increase in Angiotensin
-    1-9 and sensitization of bradykinin receptors. * NFkappaB is suppressed by SARS-Cov-2,
+  description: This pathway describes imbalances in the Renin Angiotensin System and
+    Bradykinin pathways in COVID-19.  The expression of several genes in these pathways
+    is affected in by SARS-CoV-2. SERPING1 is downregulated, which cancels the suppression
+    of F12 of the intrinsic coagulation cascade, resulting in the production of bradykinin
+    from kallikrein and KNG. ACE is downregulated, which increases bradykinin levels.
+    ACE2 is upregulated, ACE is downregulated, which causes an increase in Angiotensin
+    1-9 and sensitization of bradykinin receptors. NFkappaB is suppressed by SARS-Cov-2,
     decreasing its binding to the ACE promoter and subsequent transcription.  The
     result of a hyperactive bradykinin system is vasodilation to the point of vascular
     leakage and infiltration of inflammatory cells.  The pathway is based on Figure
-    2A from [Garvin et al.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410499/).'
+    2A from [Garvin et al.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410499/).
   keywords:
   - 20-HETE
   - ACE
@@ -108,8 +109,8 @@ schema-jsonld:
   - bradykinin, des-arg(9)
   - nitric oxide
   license: CC0
-  name: RAS and bradykinin pathways in COVID-19
+  name: Renin Angiotensin System and Bradykinin pathways in COVID-19
 seo: CreativeWork
-title: RAS and bradykinin pathways in COVID-19
+title: Renin Angiotensin System and Bradykinin pathways in COVID-19
 wpid: WP4969
 ---

_pathways/WP5609.md

@@ -26,26 +26,33 @@ annotations:
   value: citric acid cycle pathway
 authors:
 - Khanspers
+- Egonw
 citedin: ''
 communities: []
-description: draft
-last-edited: 2025-12-13
+description: Key metabolic pathways in melanoma, glycolytic pathway, TCA cycle, glutamine
+  metabolism, and oxidative phosphorylation, with potential therapeutic targets and
+  inhibitors. Inhibitors targeting critical metabolic nodes are outlined in teal.   This
+  pathway is based on [Figure 1 in Shen et al](https://www.nature.com/articles/s41420-025-02617-3).
+last-edited: 2025-12-16
 ndex: null
 organisms:
 - Homo sapiens
 redirect_from:
 - /index.php/Pathway:WP5609
 - /instance/WP5609
-- /instance/WP5609_r142197
-revision: r142197
+- /instance/WP5609_r142203
+revision: r142203
 schema-jsonld:
 - '@context': https://schema.org/
   '@id': https://wikipathways.github.io/pathways/WP5609.html
   '@type': Dataset
   creator:
     '@type': Organization
     name: WikiPathways
-  description: draft
+  description: Key metabolic pathways in melanoma, glycolytic pathway, TCA cycle,
+    glutamine metabolism, and oxidative phosphorylation, with potential therapeutic
+    targets and inhibitors. Inhibitors targeting critical metabolic nodes are outlined
+    in teal.   This pathway is based on [Figure 1 in Shen et al](https://www.nature.com/articles/s41420-025-02617-3).
   keywords:
   - 2-AAPA
   - 2-Deoxy-D-glucose